The Influence of Inhibitor Ions on Dissolution Kinetics of Al and Mg Using the Artificial Crevice Technique

This work was supported by the Strategic Environmental Research and Development Program under contract no. DACA72-99- C-0002, and the Air Force Office of Scientific Research under contract no. F49620-96-1-0479

Free volume study of poly(chlorotrifluoroethylene) using positron annihilation spectroscopy as a microanalytical tool

Positron lifetimes and X-ray diffraction measurements were carried out on poly(chlorotrifluoroethylene) films annealed between 25 and 215 degrees C. The positron lifetime results were used to determine the free volume and XRD data were used to determine the apparent crystallite size and crystallinity. The glass transition temperature (T-g) of 52 degrees C obtained from positron results is in agreement with that obtained by thermal analysis. The average free volume cell size is 74 Angstrom(3) in films annealed below T-g, and increases to 84 Angstrom(3) in samples annealed above T-g. Although the observed changes in positron lifetime parameters as a function of annealing temperature are small, they are significant for the kind of material investigated. Our observations are explained in terms of thermally activated chain mobility, local relaxations and long-range motions. We further estimate, for the first time, the activation energies in the amorphous and crystalline regions of the polymer using the Goldanskii kinetic relations. Copyright (C) 1996 Elsevier Science Ltd

Evaluation of anti-obesity activities of ethanolic extract of Terminalia paniculata bark on high fat diet-induced obese rats

Background: The prevalence and severity of obesity and associated co-morbidities are rapidly increasing across the world. Natural products-based drug intervention has been proposed as one of the crucial strategies for management of obesity ailments. This study was designed to investigate the anti-obesity activities of ethanolic extract of Terminalia paniculata bark (TPEE) on high fat diet-induced obese rats. Methods: LC-MS/MS analysis was done for ethanolic extract of T. paniculata bark. Male Sprague-Dawley (SD) rats were randomly divided into six groups of six each, normal diet fed (NC), high fat diet-fed (HFD), HFD+ orlistat (standard drug control) administered, and remaining three groups were fed with HFD + TPEE in different doses (100,150 and 200 mg/kg b. wt). For induction of obesity rats were initially fed with HFD for 9 weeks, then, (TPEE) was supplemented along with HFD for 42 days. Changes in body weight, body composition, blood glucose, insulin, tissue and serum lipid profiles, atherogenic index, liver markers, and expression of adipogenesis-related genes such as leptin, adiponectin, FAS, PPARgamma, AMPK-1alpha and SREBP-1c, were studied in experimental rats. Also, histopathological examination of adipose tissue was carried out. Results: Supplementation of TPEE reduced significantly (P < 0.05) body weight, total fat, fat percentage, atherogenic index, blood glucose, insulin, lipid profiles and liver markers in HFD-fed groups, in a dose-dependent manner. The expression of adipogenesis-related genes such as Leptin, FAS, PPARgamma, and SREBP-1c were down regulated while Adiponectin and AMPK-1alpha were up regulated in TPEE + HFD-fed rats. Furthermore, histopathological examination of adipose tissue revealed the alleviating effect of TPEE which is evident by reduced size of adipocytes. Conclusions: Together, the biochemical, histological and molecular studies unambiguously demonstrate the potential anti adipogenic and anti obesity activities of TPEE promoting it as a formidable candidate to develop anti obesity drug

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated through 96 weeks in EMERALD (NCT02269917). Virologically-suppressed, HIV-1-positive treatment-experienced adults (previous non-darunavir virologic failure [VF] allowed) were randomized (2:1) to D/C/F/TAF or boosted protease inhibitor (PI) plus emtricitabine/tenofovir-disoproxil-fumarate (F/TDF) over 48 weeks. At week 52 participants in the boosted PI arm were offered switch to D/C/F/TAF (late-switch, 44 weeks D/C/F/TAF exposure). All participants were followed on D/C/F/TAF until week 96. Efficacy endpoints were percentage cumulative protocol-defined virologic rebound (PDVR; confirmed viral load [VL] >= 50 copies/mL) and VL = 50 copies/mL (VF) (FDA-snapshot analysis). Of 1141 randomized patients, 1080 continued in the extension phase. Few patients had PDVR (D/C/F/TAF: 3.1%, 24/763 cumulative through week 96; late-switch: 2.3%, 8/352 week 52-96). Week 96 virologic suppression was 90.7% (692/763) (D/C/F/TAF) and 93.8% (330/352) (late-switch). VF was 1.2% and 1.7%, respectively. No darunavir, primary PI, tenofovir or emtricitabine resistance-associated mutations were observed post-baseline. No patients discontinued for efficacy-related reasons. Few discontinued due to adverse events (2% D/C/F/TAF arm). Improved renal and bone parameters were maintained in the D/C/F/TAF arm and observed in the late-switch arm, with small increases in total cholesterol/high-density-lipoprotein-cholesterol ratio. A study limitation was the lack of a control arm in the week 96 analysis. Through 96 weeks, D/C/F/TAF resulted in low PDVR rates, high virologic suppression rates, very few VFs, and no resistance development. Late-switch results were consistent with D/C/F/TAF week 48 results. EMERALD week 96 results confirm the efficacy, high genetic barrier to resistance and safety benefits of D/C/F/TAF

In vitro antimicrobial and antioxidant activities of bark extracts of Bauhinia purpurea

Bark extracts of Bauhinia purpurea were phytochemically analyzed and evaluated for antimicrobial and antioxidant activities. The phytochemical analysis of the bark extracts revealed the presence of alkaloids, flavonoids, steroids, saponins, triterpenes and carbohydrates. While most of them were present in methanolic and aqueous extracts, one or a few of them were present in other solvent extracts. Among different solvent extracts, aqueous extract exhibited a broad spectrum of antimicrobial activity. It showed strong antibacterial activity against Gram positive bacterial strains like Bacillus subtilis, Staphylococcus aureus and Gram negative strains like Escherichia coli and Klebsiella pneumonia and antifungal activity against Candida albicans. While methanolic extract showed moderate to strong antibacterial activity against B. subtilis, E. coli and K. pneumonia, the extracts of hexane, chloroform and ethyl acetate did not show any anti bacterial or antifungal activity against the tested fungal and bacterial strains. Antioxidant activity of the bark extracts were evaluated in terms of inhibition of free radicals by 2, 2’-diphenly-1-picrylhydrazyl (DPPH). Aqueous extract followed by methanolic extract exhibited strong to moderate antioxidant activity. The antioxidant property and antimicrobial activity of the extracts of B. purpurea against the tested microbial strains therefore, supports that there is scientific basis for their utilization in traditional medicine for wound healing and also in treatment of some infectious diseases.Key words: Bauhinia purpurea, phytochemical analysis, antimicrobial activity, antioxidant property

Optimization of single halo p-MOSFET implant parameters for improved analog performance and reliability

The effect of Channel Hot Carrier (CHC) stress under typical analog operating conditions is studied for p-MOSFETs. Our detailed characterization results show that Single Halo devices not only show improved performance, but also are immune to CHC degradation under various operating conditions

SECURE TRANSMISSION OF BIO-MEDICAL DATA USING STEGANOGRAPHY

To transmit secret data over the internet, the information should be sent in a way attacker finds it difficult to read the secret data. In this paper patient’s secret information is hidden in the bio-medical signal like ECG/EEG/PPG. The transmitted information generally contains (1) biomedical-signals (2) patient data. Main concerns include privacy and authenticity of the data being transmitted. A secret key is used which is known to sender and receiver. This paper introduces a novel steganography technique that guarantees (1) protection of private data utilizing a key and (2) originality of the bio-medical-signals. To maximize embedding, Fast-Walsh-Hadamard Transform is used to convert the signals into a set of coefficients. The proposed technique can be applied on three bio-medical signals like ECG/EEG/PPG unlike any other technique which uses only one bio-medical signal. To achieve least distortion, coefficients of least significant bit is considered. The algorithm has less impact on the bio-medical signal and the signal at the transmitting side can be recovered with less distortion

Week 48 resistance analyses of the once-daily, single-tablet regimen darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in adults living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is being investigated in two Phase III trials, AMBER (NCT02431247; treatment-naive adults) and EMERALD (NCT02269917; treatment-experienced, virologically suppressed adults). Week 48 AMBER and EMERALD resistance analyses are presented. Postbaseline samples for genotyping/phenotyping were analyzed from protocol-defined virologic failures (PDVFs) with viral load (VL) >= 400 copies/mL at failure/later time points. Post hoc analyses were deep sequencing in AMBER, and HIV-1 proviral DNA from baseline samples (VL = 3 thymidine analog-associated mutations (24% not fully susceptible to tenofovir) detected at screening. All achieved VL <50 copies/mL at week 48 or prior discontinuation. D/C/F/TAF has a high genetic barrier to resistance; no darunavir, primary PI, or tenofovir RAMs were observed through 48 weeks in AMBER and EMERALD. Only one postbaseline M184I/V RAM was observed in HIV-1 of an AMBER participant. In EMERALD, baseline archived RAMs to darunavir, emtricitabine, and tenofovir in participants with prior VF did not preclude virologic response